DCM
KERX

DAFNA Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

DAFNA Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-34,800
Closed -$443K – 87
2015
Q1 		$443K Buy
+34,800
New +$447K 0.34% 49
2014
Q3 		– Sell
-92,400
Closed -$1.42M – 63
2014
Q2 		$1.42M Sell
92,400
-7,600
-8% -$108K 1.35% 20
2014
Q1 		$1.7M Buy
100,000
+56,000
+127% +$845K 1.46% 17
2013
Q4 		$570K Sell
44,000
-30,100
-41% -$359K 0.59% 36
2013
Q3 		$748K Sell
74,100
-2,900
-4% -$25.8K 0.82% 32
2013
Q2 		$575K Buy
+77,000
New +$602K 0.84% 33

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

DAFNA Capital Management's KERX Position: Q2 2015 in Review

DAFNA Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2015, closing a stake of 34,800 shares — an estimated $443K sold.

DAFNA Capital Management first reported a position in KERX in Q2 2013 and held it in 6 quarters. The position peaked at $1.7M in Q1 2014. 153 funds tracked by Wall St. Rank hold KERX as of Q2 2015.

  • DAFNA Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • DAFNA Capital Management sold 34,800 Keryx Biopharmaceuticals Inc shares in Q2 2015, an estimated $443K.
  • DAFNA Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 6 quarters.
  • DAFNA Capital Management's Keryx Biopharmaceuticals Inc position peaked at $1.7M in Q1 2014.
  • 153 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2015.

Based on DAFNA Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.